{"product_id":"tumor-microenvironment-hardback-9780470749968","title":"Tumor Microenvironment (Hardback) 9780470749968","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eTumor Microenvironment\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eDietmar W. Siemann (Edited by), DW Siemann (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470749968, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 22 October 2010\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e464 pages\u003cbr\u003e25 x 17.4 x 2.8 cm, 0.925 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\"Overall, it would be useful to basic scientists interested in understanding the role of stroma, in particular the role of hypoxia, in cancer progression.\" (Doody's, 16 September 2011)  \u003cp\u003e \"Tumor Microenvironment is informative and current. This field of study is already evolving beyond the microenvironment into the host systemic environment and the role of endocrine factors in tumor progression. If a second edition of the book is published, it will most certainly encompass these newly emerging concepts.\" (Elsevier, 2011)\u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eThe microenvironment in which a tumor originates plays a critical role in its initiation and progression. \u003ci\u003eTumor Microenvironment\u003c\/i\u003e reviews the importance of tumor microenvironment in cancer management. Particular emphasis is placed on discussing how the unique characteristics of the tumor microenvironment not only impact disease progression and response to conventional anticancer therapies, but have also led to the identification of potential new therapeutic targets and treatment possibilities for cancer patients. \u003ci\u003eTumor Microenvironment\u003c\/i\u003e also reviews the fundamental basis of target development, preclinical assessment, and the current clinical status of these therapies.\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003eList of Contributors xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The Microenvironment in Cancer 1\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNicole N. Parker and Dietmar W. Siemann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 A highly selective process is required to obtain the cancer phenotype 1\u003c\/p\u003e \u003cp\u003e1.3 The cancer phenotype 2\u003c\/p\u003e \u003cp\u003e1.4 The extracellular matrix 3\u003c\/p\u003e \u003cp\u003e1.5 Motility, invasion, and metastatic ability 4\u003c\/p\u003e \u003cp\u003e1.6 Impact of the tumor microenvironment on the control of cancer 4\u003c\/p\u003e \u003cp\u003e1.7 Targeting the tumor microenvironment 5\u003c\/p\u003e \u003cp\u003e1.8 Summary 5\u003c\/p\u003e \u003cp\u003eReferences 6\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Establishing the Tumor Microenvironment 7\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAllison S. Betof and Mark W. Dewhirst\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 7\u003c\/p\u003e \u003cp\u003e2.2 From cancerous cells to a tumor 8\u003c\/p\u003e \u003cp\u003e2.3 A tumor is more than cancer cells and fibroblasts 9\u003c\/p\u003e \u003cp\u003e2.4 Communication between the tumor cells and stroma 11\u003c\/p\u003e \u003cp\u003e2.5 Hypoxia and angiogenesis 12\u003c\/p\u003e \u003cp\u003e2.6 Conclusion 24\u003c\/p\u003e \u003cp\u003eAcknowledgements 24\u003c\/p\u003e \u003cp\u003eReferences 24\u003c\/p\u003e \u003cp\u003eFurther reading 33\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Contributions of the Extracellular Matrix to Tumorigenesis 35\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMarie Schluterman Burdine and Rolf A. Brekken\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 The extracellular matrix 35\u003c\/p\u003e \u003cp\u003e3.2 Manipulation of the ECM during tumor development 38\u003c\/p\u003e \u003cp\u003e3.3 Matricellular proteins and their complex effects on tumor development 39\u003c\/p\u003e \u003cp\u003e3.4 Conclusion 47\u003c\/p\u003e \u003cp\u003eReferences 48\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Matrix Metalloproteinases and Their Inhibitors – Friend or Foe 53\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMumtaz V. Rojiani, Marzenna Wiranowska and Amyn M. Rojiani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 53\u003c\/p\u003e \u003cp\u003e4.2 Matrix metalloproteinases 54\u003c\/p\u003e \u003cp\u003e4.3 Tissue inhibitors of matrix metalloproteinases 63\u003c\/p\u003e \u003cp\u003e4.4 Concluding comments 69\u003c\/p\u003e \u003cp\u003eReferences 69\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Role of Tumor-Associated Macrophages (TAM) in Cancer Related Inflammation 77\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAntonio Sica and Chiara Porta\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 77\u003c\/p\u003e \u003cp\u003e5.2 Functional plasticity of macrophages 77\u003c\/p\u003e \u003cp\u003e5.3 Macrophages as key orchestrators of cancer-related inflammation 79\u003c\/p\u003e \u003cp\u003e5.4 Recruitment and differentiation of TAM 81\u003c\/p\u003e \u003cp\u003e5.5 Protumoral functions of TAM 83\u003c\/p\u003e \u003cp\u003e5.6 Molecular determinants of TAM functions 87\u003c\/p\u003e \u003cp\u003e5.7 Therapeutic targeting of TAM 89\u003c\/p\u003e \u003cp\u003e5.8 Conclusions 91\u003c\/p\u003e \u003cp\u003eReferences 92\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Bone Marrow Stroma and the Leukemic Microenvironment 99\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eWilliam B. Slayton and Zhongbo Hu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 99\u003c\/p\u003e \u003cp\u003e6.2 Components and function of the normal bone marrow microenvironment 99\u003c\/p\u003e \u003cp\u003e6.3 Leukemia and its microenvironment 119\u003c\/p\u003e \u003cp\u003e6.4 Summary 123\u003c\/p\u003e \u003cp\u003eReferences 124\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Microenvironment Factors Influencing Skeletal Metastases 135\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAlessandro Fatatis, Julia A. D’Ambrosio, Whitney L. Jamieson, Danielle L. Jernigan and Mike R. Russell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 135\u003c\/p\u003e \u003cp\u003e7.2 The bone microenvironment as a target for cancer cell dissemination 136\u003c\/p\u003e \u003cp\u003e7.3 Roles of the bone microenvironment in promoting the arrest of circulating cancer cells at the skeleton 137\u003c\/p\u003e \u003cp\u003e7.4 Concluding remarks 153\u003c\/p\u003e \u003cp\u003eReferences 153\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Premetastatic Niches 161\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eKevin L. Bennewith, Janine T. Erler and Amato J. Giaccia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 161\u003c\/p\u003e \u003cp\u003e8.2 ‘Seeds’ influencing the ‘Soil’ 162\u003c\/p\u003e \u003cp\u003e8.3 Cellular components of premetastatic niches 164\u003c\/p\u003e \u003cp\u003e8.4 ECM components of premetastatic niches 166\u003c\/p\u003e \u003cp\u003e8.5 Premetastatic niche formation precedes metastatic growth 170\u003c\/p\u003e \u003cp\u003e8.6 Therapeutic targeting of the premetastatic niche 172\u003c\/p\u003e \u003cp\u003e8.7 Evidence for premetastatic niches in the clinic 174\u003c\/p\u003e \u003cp\u003e8.8 Concluding remarks 174\u003c\/p\u003e \u003cp\u003eReferences 175\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Hypoxia, Anerobic Metabolism, and Interstitial Hypertension 183\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMichael F. Milosevic\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 183\u003c\/p\u003e \u003cp\u003e9.2 Pathophysiology of the tumor microenvironment 184\u003c\/p\u003e \u003cp\u003e9.3 Evaluating the tumor microenvironment 189\u003c\/p\u003e \u003cp\u003e9.4 Biologic and therapeutic implications 195\u003c\/p\u003e \u003cp\u003e9.5 Clinical implications 199\u003c\/p\u003e \u003cp\u003e9.6 Summary 201\u003c\/p\u003e \u003cp\u003eReferences 201\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Hypoxia and the DNA Damage Response 207\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eIsabel M. Pires, Rachel Poole and Ester M. Hammond\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 207\u003c\/p\u003e \u003cp\u003e10.2 The DNA damage response 208\u003c\/p\u003e \u003cp\u003e10.3 Hypoxia regulation of DNA repair 215\u003c\/p\u003e \u003cp\u003e10.4 Context synthetic lethality: exploiting hypoxic deregulation of DNA repair 220\u003c\/p\u003e \u003cp\u003e10.5 Conclusions 221\u003c\/p\u003e \u003cp\u003eReferences 221\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Non-Invasive Imaging of the Tumor Microenvironment 229\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBénédicte F. Jordan and Bernard Gallez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 229\u003c\/p\u003e \u003cp\u003e11.2 Imaging tumor vasculature, perfusion, and angiogenesis 229\u003c\/p\u003e \u003cp\u003e11.3 Imaging tumor hypoxia: chronic and acute 234\u003c\/p\u003e \u003cp\u003e11.4 Imaging tumor oxygen consumption 240\u003c\/p\u003e \u003cp\u003e11.5 EPR oximetry 240\u003c\/p\u003e \u003cp\u003e11.6 Imaging tumor interstitial fluid pressure (IFP) 244\u003c\/p\u003e \u003cp\u003e11.7 Imaging tumor pH 245\u003c\/p\u003e \u003cp\u003e11.8 Imaging tumor redox status 248\u003c\/p\u003e \u003cp\u003e11.9 Imaging tumor response 250\u003c\/p\u003e \u003cp\u003e11.10 Optimizing therapeutic intervention using molecular imaging 256\u003c\/p\u003e \u003cp\u003e11.11 Conclusions 261\u003c\/p\u003e \u003cp\u003eReferences 261\u003c\/p\u003e \u003cp\u003eFurther reading 270\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Hypoxia-Inducible Factor 1 (HIF1) Mediated Adaptive Responses in the Solid Tumor 271\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTereza Goliasova and Nicholas C. Denko\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 271\u003c\/p\u003e \u003cp\u003e12.2 Molecular consequences of tumor hypoxia 272\u003c\/p\u003e \u003cp\u003e12.3 Hypoxia inducible factor 1 273\u003c\/p\u003e \u003cp\u003e12.4 HIF-1 subunits and domain structure 273\u003c\/p\u003e \u003cp\u003e12.5 Regulation of HIF-1α protein stability and activity by post-translational modifications 274\u003c\/p\u003e \u003cp\u003e12.6 HIF isoforms 275\u003c\/p\u003e \u003cp\u003e12.7 Oxygen-independent HIF signaling 276\u003c\/p\u003e \u003cp\u003e12.8 HIF target genes 277\u003c\/p\u003e \u003cp\u003e12.9 Hypoxia and oxygen delivery 279\u003c\/p\u003e \u003cp\u003e12.10 Hypoxia and glucose metabolism 280\u003c\/p\u003e \u003cp\u003e12.11 Hypoxia and acidosis 281\u003c\/p\u003e \u003cp\u003e12.12 Hypoxia and metastasis 282\u003c\/p\u003e \u003cp\u003e12.13 Therapeutic implications 283\u003c\/p\u003e \u003cp\u003eReferences 285\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Regulation of the Unfolded Protein Response in Cancer 291\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJing Zhang and Albert C. Koong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 291\u003c\/p\u003e \u003cp\u003e13.2 The UPR signaling cascade 292\u003c\/p\u003e \u003cp\u003e13.3 Hypoxia activates UPR 295\u003c\/p\u003e \u003cp\u003e13.4 UPR and expression of UPR-targeted genes in cancer 298\u003c\/p\u003e \u003cp\u003e13.5 Concluding remarks 304\u003c\/p\u003e \u003cp\u003eReferences 304\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Influence of Hypoxia on Metastatic Spread 311\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRichard P. Hill and Naz Chaudary\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 311\u003c\/p\u003e \u003cp\u003e14.2 The metastatic process 313\u003c\/p\u003e \u003cp\u003e14.3 The tumor microenvironment and metastasis 316\u003c\/p\u003e \u003cp\u003e14.4 Summary 326\u003c\/p\u003e \u003cp\u003eReferences 326\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Drug Penetration and Therapeutic Resistance 329\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAndrew I. Minchinton and Alastair H. Kyle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 329\u003c\/p\u003e \u003cp\u003e15.2 Tumor microenvironment 330\u003c\/p\u003e \u003cp\u003e15.3 Drug penetration 334\u003c\/p\u003e \u003cp\u003e15.4 In vitro tumor models 338\u003c\/p\u003e \u003cp\u003e15.5 Conclusions 346\u003c\/p\u003e \u003cp\u003eReferences 347\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Impact on Radiotherapy 353\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMichael R. Horsman, Jens Overgaard and Dietmar W. Siemann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 353\u003c\/p\u003e \u003cp\u003e16.2 The tumour vasculature and microenvironment 353\u003c\/p\u003e \u003cp\u003e16.3 Influence of tumor hypoxia on radiation therapy 356\u003c\/p\u003e \u003cp\u003e16.4 Reducing hypoxia by increasing oxygen delivery 358\u003c\/p\u003e \u003cp\u003e16.5 Radiosensitizing hypoxic cells 363\u003c\/p\u003e \u003cp\u003e16.6 Killing the resistant cell population 365\u003c\/p\u003e \u003cp\u003e16.7 Vascular targeting approaches 366\u003c\/p\u003e \u003cp\u003e16.8 Conclusions and future perspectives 367\u003c\/p\u003e \u003cp\u003eReferences 368\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 HIF-1 Inhibitors for Cancer Therapy 377\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAnnamaria Rapisarda and Giovanni Melillo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 377\u003c\/p\u003e \u003cp\u003e17.2 Small molecule inhibitors of HIF- 1 378\u003c\/p\u003e \u003cp\u003e17.3 Exploiting HIF-1 inhibitors in combination strategies 391\u003c\/p\u003e \u003cp\u003e17.4 Conclusions 392\u003c\/p\u003e \u003cp\u003eAcknowledgements 392\u003c\/p\u003e \u003cp\u003eReferences 393\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Vascular-Targeted Molecular Therapy 401\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGraeme J. Dougherty and Shona T. Dougherty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 401\u003c\/p\u003e \u003cp\u003e18.2 Approaches to targeting tumor vasculature in vivo 403\u003c\/p\u003e \u003cp\u003e18.3 Alternative targeting strategies 412\u003c\/p\u003e \u003cp\u003e18.4 Concluding remarks 413\u003c\/p\u003e \u003cp\u003eAcknowledgements 413\u003c\/p\u003e \u003cp\u003eReferences 413\u003c\/p\u003e \u003cp\u003eIndex 421\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Biology, life sciences [\u003ca title=\"See our other books on Biology, life sciences\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Biology,%20life%20sciences%20%5BPS%5D%22\"\u003ePS\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52278027354392,"sku":"9780470749968","price":100.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470749968.jpg?v=1781456416","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/tumor-microenvironment-hardback-9780470749968","provider":"Freshly Printed Books","version":"1.0","type":"link"}